Alecnib 150 Mg contains Alectinib, a highly effective oral medication designed to treat ALK-positive Non Small Cell Lung Cancer Treatment (NSCLC). Alectinib is a next-generation tyrosine kinase inhibitor (TKI) specifically engineered to block the action of anaplastic lymphoma kinase (ALK), a protein responsible for cancer cell growth in certain lung cancers. Alecnib has proven to be a breakthrough treatment for…
Cerinib 150 mg contains Ceritinib, a powerful targeted therapy specifically designed for the treatment of ALK-positive non-small cell lung cancer (NSCLC). It is an oral medication used to manage advanced stages of lung cancer, particularly in patients whose cancer has spread to other parts of the body (metastatic) and who may have developed resistance to prior treatments. Ceritinib works by…
Sotoxen 120mg (Sotorasib) is a revolutionary medication designed to target and treat non-small cell lung cancer (NSCLC) with a specific genetic mutation. This targeted therapy is specifically formulated for patients whose tumors carry the KRAS G12C mutation, a previously untreatable form of lung cancer. Sotoxen works by inhibiting the KRAS protein, slowing down the growth of cancer cells, and providing…
